Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04895748
Title DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals

clear cell renal cell carcinoma


DFF332 + PBF-509 + Spartalizumab

DFF332 + Everolimus


Age Groups: adult | child | senior
Covered Countries USA | ITA | FRA | ESP

Additional content available in CKB BOOST